EP1572713A4 - Modulation antisens de l'expression de l'acyl-coa synthetase 1 - Google Patents

Modulation antisens de l'expression de l'acyl-coa synthetase 1

Info

Publication number
EP1572713A4
EP1572713A4 EP03751855A EP03751855A EP1572713A4 EP 1572713 A4 EP1572713 A4 EP 1572713A4 EP 03751855 A EP03751855 A EP 03751855A EP 03751855 A EP03751855 A EP 03751855A EP 1572713 A4 EP1572713 A4 EP 1572713A4
Authority
EP
European Patent Office
Prior art keywords
expression
acyl
acs1
coa synthetase
antisense modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03751855A
Other languages
German (de)
English (en)
Other versions
EP1572713A2 (fr
Inventor
Stuart A Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of EP1572713A2 publication Critical patent/EP1572713A2/fr
Publication of EP1572713A4 publication Critical patent/EP1572713A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés antisens, des compositions et des méthodes permettant de moduler l'expression de l'acyl-CoA synthétase 1, jusqu'ici appelée ACS1. Lesdites compositions comprennent des composés antisens, notamment des oligonucléotides antisens, ciblés sur des acides nucléiques codant pour l'ACS1. L'invention concerne des méthodes d'utilisation desdits composés pour la modulation de l'expression de l'ACS1 et pour le traitement de maladies associées à l'expression de l'ACS1.
EP03751855A 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1 Withdrawn EP1572713A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40359102P 2002-08-14 2002-08-14
US403591P 2002-08-14
PCT/US2003/025389 WO2004016749A2 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1

Publications (2)

Publication Number Publication Date
EP1572713A2 EP1572713A2 (fr) 2005-09-14
EP1572713A4 true EP1572713A4 (fr) 2006-05-24

Family

ID=31888248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03751855A Withdrawn EP1572713A4 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de l'acyl-coa synthetase 1

Country Status (7)

Country Link
EP (1) EP1572713A4 (fr)
JP (1) JP2006506976A (fr)
AU (1) AU2003269962A1 (fr)
BR (1) BR0313550A (fr)
CA (1) CA2495037A1 (fr)
MX (1) MXPA05001837A (fr)
WO (1) WO2004016749A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221671A1 (en) * 2005-05-24 2009-09-03 Sanjay Pandey Modulation of lmw-ptpase expression
US20120035242A1 (en) * 2009-01-08 2012-02-09 Shionogi & Co., Ltd. Pharmaceutical composition for treating obesity or diabetes
JP2015082971A (ja) * 2012-02-10 2015-04-30 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
WO2015020194A1 (fr) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Oligonucléotide antisens contre acsl1
JP7190794B2 (ja) 2017-03-29 2022-12-16 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
JPWO2021020412A1 (fr) 2019-07-30 2021-02-04
US20230322840A1 (en) 2020-06-15 2023-10-12 Liid Pharmaceuticals, Inc. Bridged nucleoside and nucleotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2003054159A2 (fr) * 2001-12-19 2003-07-03 Exelixis, Inc. Modulation de la signalisation des recepteurs de l'insuline par ciblage de genes de facl (acyl-coa synthetase))

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
WO2003054159A2 (fr) * 2001-12-19 2003-07-03 Exelixis, Inc. Modulation de la signalisation des recepteurs de l'insuline par ciblage de genes de facl (acyl-coa synthetase))

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 18 October 2002 (2002-10-18), "FACL1 related PCR primer SEQ ID No: 3", XP002373956, retrieved from EBI Database accession no. ADC51434 *
IKEMOTO S ET AL: "CHOLATE INHBITS HIGH-FAT DIET-INDUCED HYPERGLYCEMIA AND OBESITY WITH ACYL-COA SYNTHETASE MRNA DECREASE", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 273, no. 1, PART 1, July 1997 (1997-07-01), pages E37 - E45, XP009013253, ISSN: 0002-9513 *
LEWIN T M ET AL: "Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 27, 6 July 2001 (2001-07-06), pages 24674 - 24679, XP002269394, ISSN: 0021-9258 *
SMITH LISE ET AL: "Rational selection of antisense oligonucleotide sequences", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 11, no. 3, September 2000 (2000-09-01), pages 191 - 198, XP002372482, ISSN: 0928-0987 *
TAYLOR M F ET AL: "ANTISENSE OLIGONUCLEOTIDES: A SYSTEMATIC HIGH-THROUGHPUT APPROACH TO TARGET VALIDATION AND GENE FUNCTION DETERMINATION", DDT - DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 4, no. 12, December 1999 (1999-12-01), pages 562 - 567, XP002952061, ISSN: 1359-6446 *

Also Published As

Publication number Publication date
WO2004016749A3 (fr) 2004-08-26
MXPA05001837A (es) 2005-04-19
EP1572713A2 (fr) 2005-09-14
CA2495037A1 (fr) 2004-02-26
AU2003269962A1 (en) 2004-03-03
BR0313550A (pt) 2006-06-13
WO2004016749A2 (fr) 2004-02-26
JP2006506976A (ja) 2006-03-02
AU2003269962A8 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
WO2005049630A3 (fr) Modulation antisens de l'expression de la proteine de type kinesine 1
WO2002036743A3 (fr) Modulation antisens de l'expression de calreticuline
WO2002092772A3 (fr) Modulation antisens de l'expression de ptp1b
WO2004044181A3 (fr) Modulation antisens de l'expression d'apolipoproteine b
EP1190099A4 (fr) Modulation antisens de l'expression de pi3k p85
WO2004071407A3 (fr) Modulation antisens de l'expression de ptp1b
WO2004011610A3 (fr) Modulation antisens de l'expression de kinase de type polo
WO2003097662A8 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2002010378A3 (fr) Modulation antisens de l'expression de ptp1b
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c
EP1250347A4 (fr) Modulation antisens de l'expression de akt-3
WO2003088921A3 (fr) Modulation antisens de l'expression d'hydroxysteroide 11-beta deshydrogenase 1
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1
WO2004010956A3 (fr) Modulation par antisens d'expression de lar
WO2004016749A3 (fr) Modulation antisens de l'expression de l'acyl-coa synthetase 1
WO2003099224A3 (fr) Modulation antisens de l'expression de la kinesine de type 1
EP1235924A4 (fr) Modulation antisens de l'expression de l'activateur du recepteur de facteur kappa b nucleaire (rank)
WO2003027229A3 (fr) Modulation antisens de l'expression de rip2
WO2003040161A3 (fr) Modulation antisens de l'expression du facteur de transcription activateur 3
WO2004014299A3 (fr) Modulation antisens de l'expression de la resistine
WO2003031576A3 (fr) Modulation antisens de l'expression de l'inhibiteur kappa b kinase-gamma
WO2003099204A3 (fr) Modulation anti-sens de l'expression inhibiteur kappa b kinase-beta
WO2004015126A3 (fr) Modulation antisens de l'expression d'edg

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060609